Therapy optimisation trial for the treatment of acute myeloid leukaemia

Acute myeloid leukaemia (AML) is a rare type of blood cancer in children and adolescents. The disease originates in the bone marrow, where normal blood formation is disturbed by an uncontrolled multiplication of immature blood cells. Without therapy, AML leads to serious diseases and organ dysfunction with a fatal outcome.

Aim of the trial

The aim of MyeChild 01 is to improve the treatment and chances of recovery of AML patients. In an attempt to keep the side effects of the therapy as low as possible, medical professionals try, on the one hand, to reduce the intensity and duration of treatment. On the other hand, however, every child should be treated as often and as long as necessary for the leukaemia to be overcome on a permanent basis. In addition, research projects are being carried out to better understand the biology of AML in children and adolescents and to investigate new methods of diagnosis and treatment.

Implementing organisation

Swiss Paediatric Oncology Group (SPOG)